This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Detková, D Articles by Pascual-Salcedo, D Search for Related Content PubMed PubMed Citation Articles by Detková, D Articles by Pascual-Salcedo, D Social Bookmarking                         What's this?

Do antibodies to ß2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?

Immunology Unit, Department of Internal Medicine and Hematology Service, Hospital La Paz, Madrid, Spain

A Gil-Aguado

P Lavilla

Department of Internal Medicine and Hematology Service, Hospital La Paz, Madrid, Spain

M V Cuesta

Hematology Service, Hospital La Paz, Madrid, Spain

G Fontaán

D Pascual-Salcedo

Immunology Unit, Department of Internal Medicine and Hematology Service, Hospital La Paz, Madrid, Spain

The aim of this study was to determine if the measurement of anti-ß2-glycoprotein I antibodies (aß2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose aß2-GPI of both isotypes was measured in 42 patients with APS and 32 SLE patients without APS. Clinical records of all patients were thoroughly reviewed. The presence of aß2-GPI was correlated with the clinical manifestations of APS and compared with the presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) activity.

There was a positive correlation between levels of aCL and aß2-GPI for both IgG and IgM isotypes (r of Spearman = 0.82 and 0.64 respectively, P = 0.0001). Both antibodies presented significantly higher titres in LA positive patients (P 0.05).

The specificity for APS was 91% for IgG aß2-GPI vs 75% for IgG aCL and 87% for IgM aß2-GPI vs 81% for IgM aCL. 68% of patients with thrombosis of 100% of patients with thrombocytopenia showed positive tests for all three markers (aCL, LA, aß2-GPI). Simultaneous presence of circulating LA and high titres of both aCL and aß2-GPI identify a subset of patients with primary APS (PAPS) who have a more severe clinical course of the disease. Although the specificity of aß2-GPI IgG is higher than that of aCL IgG, when all three tests are performed aß2-GPI testing provides only additional information to that of aCL and LA. Therefore, we concluded that the aß2-GPI test should not be considered as a substitute for conventional LA or aCL assays. However, performance of aß2-GPI seems to be important in PAPS with high aCL titres, to alert the physician about the risk for the worst course of the illness.

Key Words: antiphospholipid syndrome • antiphospholipid antibodies • anticardiolipin antibodies • lupus anticoagulant • anti-ß2-glycoprotein I antibodies

Lupus, Vol. 8, No. 6, 430-438 (1999)
DOI: 10.1177/096120339900800604


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis How we diagnose the antiphospholipid syndrome Blood, January 29, 2009; 113(5): 985 - 994. [Abstract] [Full Text] [PDF]

				C. Neville, J. Rauch, J. Kassis, S. Solymoss, L. Joseph, P. Belisle, R. Subang, E. R. Chang, and P. R. Fortin The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-{beta}2-glycoprotein I antibodies Rheumatology, September 1, 2006; 45(9): 1116 - 1120. [Abstract] [Full Text] [PDF]

				M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]

				H Guglielmone, S Vitozzi, O Elbarcha, and E Fernandez Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections Ann Rheum Dis, May 1, 2001; 60(5): 500 - 504. [Abstract] [Full Text] [PDF]

				V Aguirre, R Cuchacovich, L Barria, H Aris, C Trejo, L Massardo, R Pasten, and L Espinoza Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE) Lupus, February 1, 2001; 10(2): 75 - 80. [Abstract] [PDF]

				A Shrivastava, S Dwivedi, A Aggarwal, and R Misra Anti-cardiolipin and anti-beta 2 glycoprotein Iantibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures Lupus, January 1, 2001; 10(1): 45 - 50. [Abstract] [PDF]